A spinoff from the Computational Biology Institute at George Washington Universityâs Virginia Science and Technology Campus, the company combines genomics and informatics to produce faster and more accurate results than culture-based or even other molecular-based diagnostic approaches. From a single test, Aperiomics can simultaneously test for all pathogens, whether bacteria, virus, fungus or parasite. The sample can be tissue, plant, animal, or environmental. Based on its process that capitalizes on high-throughput Next-generation genomic sequencing and advanced Bayesian statistics, Aperiomics can also reveal that a formerly unknown pathogen. This effective system translates into improved human and animal health, reduced risk to public health, and significant health care cost savings. Perhaps unique in the factthatthe firm combines advanced DNA testing, the power of big data and decades of infectious disease expertise, Aperiomics is radically changing how medical professionals identify infections. Aperiomics is strucrured to identify every known bacteria, virus, fungus, and parasite through deep shotgun metagenomic sequencing, using its proprietary, world-renowned database containing over 37,000 microorganisms. Helping doctors and their patients identify the causes of infections that other tests cannot identify, Aperiomics streamlines the path to a positive clinical outcome. Responsible for solving more than 1,000 medical mysteries, patients and their physicians often contact Aperiomics after suffering with medical conditions for years and hearing about Aperiomics' life-changing success stories. Aperiomics was named Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018
